Cantor Fitzgerald analyst Eric Schmidt reiterated an Overweight rating on ADC Therapeutics (NYSE: ADCT).The analyst commented, "ADCT announced that Zynlonta ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE